|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.36 USD | -5.71% |
|
-6.31% | -1.88% |
| Jun. 13 | Tonix Pharmaceuticals Holding Corp. Appoints James ?Jim? Hunter to Board of Directors, Effective June 12, 2025 | CI |
| Jun. 12 | Top Premarket Decliners | MT |
| Capitalization | 240M 208M 196M 178M 329M 20.74B 372M 2.31B 887M 9.5B 899M 880M 35B | P/E ratio 2025 * |
-2.64x | P/E ratio 2026 * | -5.33x |
|---|---|---|---|---|---|
| Enterprise value | 240M 208M 196M 178M 329M 20.74B 372M 2.31B 887M 9.5B 899M 880M 35B | EV / Sales 2025 * |
19.7x | EV / Sales 2026 * | 2.93x |
| Free-Float |
99.94% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
More press releases
| 1 day | -5.71% | ||
| 1 week | -6.31% | ||
| Current month | -18.65% | ||
| 1 month | +21.65% | ||
| 3 months | +96.48% | ||
| 6 months | -43.23% | ||
| Current year | -1.88% |
| 1 week | 31.35 |  | 37.42 |
| 1 month | 25.4 | | 44.3 |
| Current year | 6.76 | | 58.3 |
| 1 year | 6.76 | | 137 |
| 3 years | 6.76 | | 44,800 |
| 5 years | 6.76 | | 1,000,000 |
| 10 years | 6.76 | | 1,000,000 |
| Manager | Title | Age | Since |
|---|---|---|---|
Seth Lederman
CEO | Chief Executive Officer | 67 | 2007-11-15 |
Bradley Saenger
DFI | Director of Finance/CFO | 51 | 2016-01-31 |
Siobhan Fogarty
CTO | Chief Tech/Sci/R&D Officer | 56 | 2025-02-03 |
| Director | Title | Age | Since |
|---|---|---|---|
Seth Lederman
CHM | Chairman | 67 | 2011-09-30 |
Margaret Bell
BRD | Director/Board Member | 65 | 2017-09-11 |
Adeoye Olukotun
BRD | Director/Board Member | 80 | 2018-09-04 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -5.71% | -6.31% | -73.48% | -99.91% | 254M | ||
| +0.63% | -0.35% | -18.02% | -6.16% | 74.6B | ||
| +1.70% | +1.60% | +34.57% | +22.12% | 51.48B | ||
| -0.10% | -3.70% | +13.27% | +100.64% | 34.36B | ||
| +0.40% | -3.98% | -43.20% | -37.03% | 18.54B | ||
| -0.96% | -3.78% | +103.67% | +188.85% | 16.51B | ||
| +0.78% | -4.99% | +52.94% | +725.40% | 14.98B | ||
| -0.04% | -.--% | +74.71% | +140.03% | 14.02B | ||
| +0.28% | -1.10% | +11.43% | -3.94% | 13.22B | ||
| +1.62% | -6.86% | -4.44% | -41.91% | 10.75B | ||
| Average | -0.14% | -2.85% | +15.15% | +98.81% | 24.87B | |
| Weighted average by Cap. | +0.62% | -1.72% | +14.99% | +75.86% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 12.16M 10.56M 9.94M 9.04M 16.7M 1.05B 18.85M 117M 45M 482M 45.62M 44.65M 1.78B | 81.7M 70.93M 66.8M 60.76M 112M 7.07B 127M 788M 302M 3.24B 307M 300M 11.93B |
| Net income | -98.93M -85.88M -80.89M -73.58M -136M -8.56B -153M -955M -366M -3.92B -371M -363M -14.45B | -89.7M -77.87M -73.34M -66.71M -123M -7.76B -139M -866M -332M -3.56B -337M -329M -13.1B |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
81
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-06-20 | 32.36 $ | -5.71% | 508,732 |
| 25-06-18 | 34.32 $ | -1.72% | 480,999 |
| 25-06-17 | 34.92 $ | -5.55% | 415,907 |
| 25-06-16 | 36.97 $ | +15.60% | 740,179 |
| 25-06-13 | 31.98 $ | -7.41% | 684,867 |
Delayed Quote Nasdaq, June 20, 2025 at 04:00 pm EDT
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
32.36USD
Average target price
61.67USD
Spread / Average Target
+90.56%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TNXP Stock
Select your edition
All financial news and data tailored to specific country editions
